```mermaid
flowchart TD
AQP4["AQP4<br/>Aquaporin-4<br/>Water Channel"]
BBB["Blood-Brain<br/>Barrier"]
Astrocytes["Astrocytes<br/>Glial Cells"]
WaterHome["Water<br/>Homeostasis"]
MS["Multiple Sclerosis<br/>Demyelination"]
Neuroinflam["Neuroinflammation<br/>Immune Response"]
Autoimmune["Autoimmune<br/>Attack"]
ALS["Amyotrophic<br/>Lateral Sclerosis"]
Alzheimer["Alzheimer's<br/>Disease"]
TBI["Traumatic<br/>Brain Injury"]
Stroke["Stroke<br/>Ischemia"]
BrainEdema["Brain Edema<br/>Swelling"]
GlymphClear["Glymphatic<br/>Clearance"]
Aging["Aging<br/>Process"]
Dementia["Dementia<br/>Cognitive Decline"]
Neurodegeneration["Neurodegeneration<br/>Cell Death"]
AQP4 -->|"expressed_in"| Astrocytes
AQP4 -->|"localizes_to"| BBB
AQP4 -->|"regulates"| WaterHome
AQP4 -->|"facilitates"| GlymphClear
AQP4 -->|"associated_with"| MS
AQP4 -->|"therapeutic_target"| Neuroinflam
AQP4 -->|"activates"| Autoimmune
AQP4 -->|"therapeutic_target"| ALS
AQP4 -->|"expressed_in"| Alzheimer
AQP4 -->|"associated_with"| TBI
AQP4 -->|"associated_with"| Stroke
WaterHome -->|"dysregulation_leads_to"| BrainEdema
Neuroinflam -->|"promotes"| MS
Autoimmune -->|"targets"| AQP4
TBI -->|"causes"| BrainEdema
Stroke -->|"causes"| BrainEdema
AQP4 -->|"inhibits"| Aging
GlymphClear -->|"impairment_leads_to"| Alzheimer
Alzheimer -->|"progression_to"| Dementia
MS -->|"leads_to"| Neurodegene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AQP4 — Aquaporin-4</th>
</tr>
<tr> [^5]
<td class="label">Symbol</td> [^6]
<td><strong>AQP4</strong></td> [^7]
</tr> [^8]
<tr> [^9]
<td class="label">Full Name</td> [^10]
<td>Aquaporin-4</td> [^11]
</tr> [^12]
<tr> [^13]
<td class="label">Chromosome</td> [^14]
<td>18q11.2</td> [@external]
</tr> [^16]
<tr> [^17]
<td class="label">NCBI Gene</td> [^18]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/361" target="_blank">361</a></td> [^19]
</tr> [^20]
<tr> [^21]
<td class="label">Ensembl</td> [^22]
<td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171885" target="_blank">ENSG00000171885</a></td> [@ncbi]
</tr> [@genecards]
<tr> [@omim]
<td class="label">OMIM</td> [@allen]
<td><a href="https://www.omim.org/entry/600308" target="_blank">600308</a></td> [@ensembl]
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P55087" target="_blank">P55087</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers) (modifier), [NMOSD](/diseases/neuromyelitis-optica) (autoimmune target), [TBI](/diseases/traumatic-brain-injury) (edema)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Astrocytes](/cell-types/astrocytes) (perivascular endfeet), Ependyma, Kidney collecting duct</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-807d7a82" style="color:#ce93d8" title="Score: 0.60">SASP-Driven Aquaporin-4 Dysregulation...</a><br><a href="/hypothesis/h-62e56eb9" style="color:#ce93d8" title="Score: 0.53">Glymphatic System-Enhanced Antibody Clea...</a><br><a href="/hypothesis/h-c8ccbee8" style="color:#ce93d8" title="Score: 0.46">Aquaporin-4 Polarization Rescue...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">924 edges</a></td>
</tr>
</table>
Aqp4 (Aquaporin 4 Gene) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
AQP4 encodes aquaporin-4, the most abundant water channel in the central nervous system and the primary mediator of transmembrane water transport in the brain. The gene is located on chromosome 18q11.2, spans approximately 13.5 kb, and contains 5 exons with alternative first exons generating two major isoforms (M1 and M23) from a single transcript ([Jung et al., 1994](https://doi.org/10.1074/jbc.269.20.14648)).
AQP4 has gained major attention in neurodegenerative disease research due to three key discoveries: (1) the [aqp4](/proteins/aqp4) is essential for [glymphatic system](/entities/glymphatic-system) function — the brain's waste clearance pathway that removes [Amyloid-Beta](/proteins/amyloid-beta), tau]/proteins/tau], and other metabolic waste during sleep ([Iliff et al., 2012](https://doi.org/10.1126/scitranslmed.3003748)); (2) AQP4 SNPs modify [alzheimers](/diseases/alzheimers-disease) risk, amyloid burden, and cognitive decline trajectory, likely through effects on glymphatic efficiency ([Burfeind et al., 2017](https://doi.org/10.1016/j.trci.2017.05.001)); and (3) AQP4 is the target autoantigen in [nmosd](/diseases/nmosd), where anti-AQP4 antibodies destroy perivascular [astrocytes](/cell-types/astrocytes).
[aqp4](/proteins/aqp4) is a transmembrane water channel of the aquaporin (MIP) family:
AQP4 at perivascular [astrocytes](/cell-types/astrocytes) endfeet is essential for [glymphatic clearance]:
Two major protein isoforms are generated from alternative translation initiation sites within the same mRNA, plus a recently discovered readthrough isoform:
| Isoform | Start Codon | Size | Function |
|---|---|---|---|
| M1 | Met-1 (exon 0) | 323 aa | Restricts OAP size; widely distributed |
| M23 | Met-23 (exon 1) | 301 aa | Forms large OAPs; enriched in perivascular endfeet |
| AQP4ex | Readthrough past stop codon | 326 aa | Extended C-terminus; required for perivascular polarization |
The M23:M1 ratio determines OAP size and is tightly regulated in different brain compartments.
The extended isoform AQP4ex is generated by translational readthrough of the canonical stop codon, producing a protein with an additional 29 C-terminal amino acids. AQP4ex is specifically required for perivascular AQP4 anchoring — mice lacking AQP4ex show near-complete loss of perivascular AQP4 polarization while retaining normal total AQP4 expression levels. This isoform has emerged as a potential therapeutic target: enhancing AQP4ex production or preventing its degradation could restore perivascular polarization and glymphatic clearance in aging and [alzheimers](/diseases/alzheimers-disease) ([Palazzo et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37821965/)).
In healthy brain, AQP4 is highly polarized to perivascular astrocyte endfeet, creating a concentration gradient that drives directional water flow from perivascular CSF into the interstitium. This polarization depends on the dystrophin-associated protein complex (DAPC), which anchors AQP4 (particularly AQP4ex and M23) to the perivascular membrane through alpha-syntrophin and dystroglycan.
Aging is associated with progressive loss of perivascular AQP4 polarization:
In neurodegenerative conditions, reactive [astrocytes](/cell-types/astrocytes) show dramatic AQP4 depolarization, with redistribution of AQP4 from endfeet to the entire astrocytic membrane. This reactive astrocyte phenotype creates a positive feedback loop: AQP4 depolarization impairs waste clearance, which promotes further protein aggregation, which drives more astrogliosis and additional AQP4 redistribution.
The glymphatic system operates primarily during sleep, when interstitial space volume expands by ~60% due to noradrenergic-mediated changes in cell volume, facilitating convective flow through AQP4-lined channels. AQP4 deletion abolishes the sleep-wake difference in glymphatic clearance, demonstrating that AQP4 is the molecular effector of sleep-dependent brain waste removal.
Sleep deprivation causes non-adaptive changes in AQP4 localization:
AQP4 genetic variation moderates the relationship between poor sleep and brain [amyloid-beta](/proteins/amyloid-beta) burden. Individuals with specific AQP4 risk alleles show stronger associations between sleep disruption and amyloid accumulation, consistent with impaired glymphatic clearance during sleep ([Rainey-Smith et al., 2018](https://doi.org/10.1038/s41398-018-0094-x)). This gene-environment interaction suggests that AQP4 genotype may identify individuals particularly vulnerable to sleep disruption-mediated neurodegeneration.
Multiple AQP4 SNPs modify AD risk and progression:
Key variant studies:
| SNP | Location | Effect | Reference |
|---|---|---|---|
| rs3875089 | Promoter (exon 1/M23) | Associated with altered amyloid PET burden | [Burfeind et al., 2020](https://doi.org/10.1073/pnas.1901077117) |
| rs3763040 | Promoter (exon 1) | Associated with faster cognitive decline after AD diagnosis | [Burfeind et al., 2017](https://doi.org/10.1016/j.trci.2017.05.001) |
| rs9951307 | 3-prime region | Associated with slower cognitive decline | [Burfeind et al., 2017](https://doi.org/10.1016/j.trci.2017.05.001) |
| rs3763043 | 3-prime UTR | Associated with more rapid cognitive decline | [Burfeind et al., 2017](https://doi.org/10.1016/j.trci.2017.05.001) |
| rs335929 | 3-prime UTR | Associated with [parkinsons](/diseases/parkinsons-disease) risk | [Liu et al., 2023](https://doi.org/10.1016/j.neulet.2023.137132) |
A 2024 machine learning study identified an AQP4 polymorphism-based risk score that predicts early brain amyloid aggregation, with sex-dependent effects — certain haplotypes conferring higher risk in females.
A 2025 study found that AQP4 SNPs influence longitudinal white matter free water accumulation and cognitive decline in non-demented older adults, providing in vivo evidence that AQP4 genetic variation affects brain fluid dynamics independently of amyloid pathology ([Katsuse et al., 2025](https://doi.org/10.1002/alz.14567)).
AQP4 is the target autoantigen in [nmosd](/diseases/nmosd):
AQP4 has dual roles in brain edema:
AQP4 variants (particularly rs335929) have been associated with [parkinsons](/diseases/parkinsons-disease) risk. Impaired glymphatic clearance due to AQP4 dysfunction may contribute to the accumulation of [alpha-synuclein](/proteins/alpha-synuclein) in the PD brain, though the relationship is less established than for Alzheimer's Disease.
Emerging pharmaceutical approaches aim to restore or enhance AQP4-mediated glymphatic clearance:
Non-invasive 40 Hz light and sound stimulation (gamma entrainment) enhances glymphatic flow through a mechanism involving adenosine A2A receptor (A2AR) signaling and enhanced AQP4-mediated perivascular exchange. Multiple clinical trials are evaluating 40 Hz stimulation in [alzheimers](/diseases/alzheimers-disease) patients, with glymphatic enhancement mediated through AQP4 as a proposed mechanism of action.
Given AQP4's critical role in sleep-dependent waste clearance, therapeutic strategies to improve sleep quality and duration represent an indirect approach to optimizing AQP4-mediated glymphatic function. This is particularly relevant for individuals carrying AQP4 risk alleles who show enhanced vulnerability to sleep disruption-mediated amyloid accumulation.
MMP-mediated degradation of the perivascular basement membrane disrupts AQP4 anchoring. MMP inhibitors may preserve perivascular AQP4 polarization and glymphatic function in neuroinflammatory conditions.
Mesenchymal stem cell-derived [exosomes](/entities/exosomes) have shown promise in restoring AQP4 perivascular polarization in preclinical models, possibly through delivery of DAPC components or anti-inflammatory factors that reduce reactive astrogliosis.
In the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=AQP4):
The study of Aqp4 (Aquaporin 4 Gene) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate